We were not able to find an announced earnings date for this symbol yet. Check back again later
Company Info
CEO
N/A
Location
Florida, USA
Exchange
OTC
Website
https://organicell.com
Summary
Organicell Regenerative Medicine, Inc.
Company Info
CEO
N/A
Location
Florida, USA
Exchange
OTC
Website
https://organicell.com
Summary
Organicell Regenerative Medicine, Inc.
AI Insights for ZEOX
5 min read
Quick Summary
ZEO ScientifiX Inc., formerly Organicell Regenerative Medicine, Inc., is a clinical-stage biopharmaceutical company focused on regenerative medicine and biological therapeutics. The company develops products derived from perinatal tissues, patient blood, and exosome-related science for chronic, degenerative, respiratory, orthopedic, wound care, pain management, and inflammatory conditions. Its historical lead candidate is Zofin™, an acellular biologic derived from perinatal sources and designed to preserve naturally occurring microRNAs, growth factors, cytokines, chemokines, exosomes, nanoparticles, hyaluronic acid, and proteins without added substances or diluents. The company also markets regenerative medicine services and supports healthcare providers through education, advertising, and related commercialization services. Its main customers and partners are physicians, regenerative medicine clinics, healthcare providers, clinical research sites, and potentially patients seeking physician-administered biologic therapies, especially in Florida and other markets where compliant regenerative treatments are available.
Strengths
•
ZEO’s primary strength is its focused position in regenerative medicine, an area with strong patient and physician interest.
•
The company has products and research programs involving exosomes, perinatal biologics, autologous blood-derived products, and tissue-derived therapeutic approaches.
•
Its reported gross profit is positive, suggesting that its revenue-generating activities may have attractive gross margins even though the company is not yet consistently profitable.
•
The company also benefits from its Florida location, especially after SB 1768 created a more permissive state-level framework for certain physician-administered stem cell and human tissue-derived therapies.
•
Its association with Nova Southeastern University facilities, cGMP-compliant manufacturing claims, and collaborations with research organizations may help support credibility if matched by strong data and transparent regulatory execution.
Risks
•
ZEO’s main weakness is that it remains a very small OTC-traded company with limited revenue, negative EPS, and negative operating income.
•
The company’s market capitalization is modest, and the reported trading volume is low, which can create liquidity risk and significant price volatility for investors.
•
Its therapeutic candidates are still dependent on clinical validation, and early-stage or small studies do not guarantee regulatory approval, reimbursement, or broad physician adoption.
•
The company also faces competition from better-capitalized regenerative medicine firms, established tissue-product companies, academic medical centers, and private clinics.
•
In addition, reliance on evolving regulatory interpretations around exosomes, perinatal biologics, autologous products, and stem cell-related therapies creates uncertainty around commercialization strategy.
Key Risks
•
ZEO faces substantial regulatory risk because regenerative medicine products, exosomes, human cells, tissues, and cellular or tissue-based products can be subject to complex FDA rules.
•
A favorable state law does not eliminate federal regulatory requirements, and any mismatch between commercial activity and FDA expectations could lead to enforcement, delays, or reputational harm.
•
Clinical risk is also high because early research may not translate into statistically meaningful safety and efficacy results in larger controlled studies.
•
Financial risk is significant because the company is loss-making, small, and may need additional capital, which could dilute shareholders.
What to Watch
The most recent reported fundamentals show ZEO as a small, revenue-generating but still loss-making regenerative medicine company.
For the reported quarter, total revenue was $2.581 million, total gross profit was $2.055 million, total operating income was negative $512,000, and net income was negative $145,000.
Basic and diluted EPS were negative $0.02, indicating that the company has not yet reached consistent profitability.
The company’s stock trades on the OTC market under ZEOX after FINRA processed the name and ticker change from Organicell Regenerative Medicine, Inc. and OCEL to ZEO ScientifiX, Inc. and ZEOX.
Key operational themes included advancing biologic therapeutics, emphasizing PPX™, discussing Phase 2 ambitions, and positioning the company to benefit from Florida’s new stem cell law and expanded regenerative medicine demand.
Price Drivers
•
ZEOX’s stock price is likely driven primarily by clinical trial progress, regulatory developments, financing activity, and investor sentiment toward regenerative medicine microcap stocks.
•
The company has a small market capitalization of about $11.3 million, which can make the shares highly sensitive to small changes in volume, news flow, or investor demand.
•
Its reported operating revenue of $2.581 million and gross profit of $2.055 million show some commercial activity, but net income and operating income remain negative, which makes earnings quality and cash runway important valuation factors.
•
Announcements involving Phase 2 trial plans, PPX™ enrollment, Florida SB 1768 adoption, facility expansion, or real-world outcomes data could support the share price if investors view them as credible growth catalysts.
•
Conversely, weak enrollment, regulatory scrutiny, dilution, low liquidity, or disappointing clinical results could pressure the stock sharply because OTC securities often trade with wider spreads and lower institutional participation.
Recent News
•
ZEO ScientifiX announced that FINRA completed the corporate action changing the company’s name from Organicell Regenerative Medicine, Inc. to ZEO ScientifiX, Inc. and changing its OTCQB ticker from OCEL to ZEOX.
•
The company said the change became effective at the opening of trading on March 5, 2024, while the CUSIP remained unchanged.
•
Management stated that the new name reflects the company’s growth strategy and its focus on advancing biologic therapeutics, including Zofin™ and PPX™.
•
ZEO also announced that it is preparing to benefit from Florida’s SB 1768, which took effect July 1, 2025 and allows certain physician-administered non-FDA-approved stem cell and human tissue-derived therapies under specific conditions.
•
The company highlighted an IRB-approved PPX™ study for musculoskeletal joint conditions, potential laboratory expansion at Nova Southeastern University, and the possibility of using real-world patient data to support future research and regulatory efforts.
Market Trends
•
The broader regenerative medicine market is being shaped by strong patient demand for alternatives to conventional drugs, surgery, and chronic pain management approaches.
•
Exosome science, autologous blood-derived products, perinatal biologics, and tissue-derived therapies are attracting interest, but they remain under close regulatory scrutiny.
•
State-level policy changes, such as Florida’s SB 1768, may encourage more physician adoption and medical tourism, although federal FDA oversight remains a major constraint.
•
Investors are increasingly selective in biotechnology and regenerative medicine because funding costs are higher, clinical timelines are long, and many early-stage companies require repeated capital raises.
•
Companies that can show credible safety data, reproducible manufacturing, compliant commercialization, and meaningful clinical outcomes are more likely to benefit from the sector’s growth than companies relying only on promotional narratives.
AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.
Community Research
Research from investors like you
Be the first to share your analysis on ZEOX
Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.